Metabolism News and Research

Latest Metabolism News and Research

Study on differential aspects of cardiac insufficiency due to high blood pressure amongst women and men

Doctor Elena Zubillaga studied 109 women and 120 men admitted to hospital with a cardiac insufficiency solely due to high blood pressure. More concretely, she analysed the clinical, biochemical and ecocardiographical differences between the patients, depending on their sex. She also made reference to the data provided by serum markers for the metabolism of the collagen in the heart and the systolic function or contraction of the latter, as alterations taking place in the metabolism of myocardial collagen are associated with certain clinical situations.

18 Aug 2010

Xcelligence System provides real-time detection of neuronal cell death

Time course analyses of neuronal cell death and its underlying mechanisms require laborious experiments and multiple endpoint assays, often involving labelling with irritating compounds and cell disruption. A recent study used the xCELLigence System of Roche to investigate the response of the neuronal-like cell line HT-22 and cultured primary rat cortical neurons to different cell death stimuli and neuroprotectants.

18 Aug 2010

Genome-wide study identifies key genetic variant associated with nonalcoholic fatty liver disease

Researchers at Massachusetts General Hospital found that patients with nonalcoholic fatty liver disease (NAFLD) who carry an allele of the PNPLA3 gene have an increased risk of developing advanced disease, including nonalcoholic steatohepatitis (NASH), fibrosis, and cirrhosis. A second study supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) validates these findings and further concludes that in pediatric patients, the same allele is associated with earlier disease presentation.

18 Aug 2010

Research confirms genetic link to advanced fatty liver disease

17 Aug 2010

Pisgah Labs receives Notice of Allowance for new patent relating to thyroid hormone drugs

Today, Pisgah Labs, Inc. received a Notice of Allowance from the United States Patent and Trademark office for an important new technology patent addressing global stability problems of thyroid hormone drugs.

17 Aug 2010

Xenon Pharmaceuticals commences phase 2 clinical trial of XEN402 therapy for PHN

Xenon Pharmaceuticals Inc. announced today that it has initiated a phase 2 clinical trial evaluating its novel topical XEN402 therapy for the treatment of PHN.

17 Aug 2010

Zebrafish-yeast approach for studying copper deficiency, complex multifactorial diseases

Copper deficiency diseases can be devastating. Symptoms can range from crippling neurological degeneration in Menkes disease ,a classic copper deficiency disease to brittle bones, anaemia and defective skin pigmentation in gastric bypass patients. Unfortunately, very little is known about how the body uses this essential nutrient. Knowing that melanocytes (the cells that give rise to hair, skin and eye pigmentation) are dramatically affected by the effects of copper deficiency, Elizabeth Patton from the University of Edinburgh, UK, and other colleagues from UK and US based labs decided to find out how melanocytes metabolise copper.

17 Aug 2010

Ancient discovery holds key to joint tissue regeneration

Osteoarthritis is a crippling disease worldwide, with an estimated eight million sufferers in the UK alone. It has been described as like "wearing a suit of rusty armour," with unrelenting, razor-like pain.

17 Aug 2010

Albert Einstein College of Medicine named 1 of 5 Nathan Shock Centers

Albert Einstein College of Medicine of Yeshiva University has been named one of the National Institutes of Health's (NIH) Nathan Shock Centers of Excellence in the Basic Biology of Aging. The select group of five centers nationwide provides leadership in the pursuit of basic research into the biology of aging. Einstein's designation includes a $3.1 million, five-year grant from the NIH's National Institute on Aging.

17 Aug 2010

SIK2 impacts cell division cycle, regulates ovarian cancer response to chemotherapy: Research

For the first time, Salt Inducible Kinase 2 (SIK2) has been found to play a critical role in cell division and to regulate the response of some ovarian cancers to chemotherapy.Findings were reported by researchers from The University of Texas MD Anderson Cancer Center in the August issue of Cancer Cell. The study adds to growing evidence that combination therapies targeting different phases of the cell division cycle are vital for optimal cancer treatment.

17 Aug 2010

$Study finds first clue that links childhood obesity to skeletal fractures$

Study finds first clue that links childhood obesity to skeletal fractures

Children at risk for diabetes before they reach puberty also appear to be at risk for weak bones, Medical College of Georgia researchers report.

16 Aug 2010

Study examines impact of microvascular decompression surgery for type 2 diabetes

A team of Allegheny General Hospital (AGH) physicians led by neurosurgical pioneer Peter Jannetta, MD, has made an important new discovery linking the central nervous system to the onset and progression of type 2 diabetes mellitus.Reporting today in the journal Surgical Neurology International, Dr. Jannetta and his colleagues present evidence from a prospective clinical trial that vascular compression of a section of the brain called the medulla oblongata is a factor in some patients with type 2 diabetes and that microvascular decompression surgery (MVD) may be an effective treatment for the condition.

13 Aug 2010

Scientists develop new metabolite analysis technique for accurate ovarian cancer detection

Scientists at the Georgia Institute of Technology have attained very promising results on their initial investigations of a new test for ovarian cancer. Using a new technique involving mass spectrometry of a single drop of blood serum, the test correctly identified women with ovarian cancer in 100 percent of the patients tested. The results can be found online in the journal Cancer Epidemiology, Biomarkers, & Prevention Research.

12 Aug 2010

USPTO allows Regulus Therapeutics' claims of key Tuschl III patent covering Mir-155

Regulus Therapeutics Inc. announced today that the United States Patent and Trademark Office has allowed claims in a patent application (US Serial No. 12/550,579) derived from the "Tuschl III" patent series. The allowed claims relate to human microRNA miR-155, a microRNA that is a potential target for immuno-inflammatory indications, and a lead program of the Regulus-GSK Strategic Alliance.

11 Aug 2010

Entelos receives patent for PhysioLab virtual patient technology

Entelos, Inc. today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 7,774,182, entitled "Apparatus and Method for Validating a Computer Model." This patent was issued to Entelos for its invention of an innovative computer-implemented method for validating multiple virtual patients within a computer model. The PhysioLab virtual patient technology allows Entelos life scientists and engineers to more rapidly evaluate the safety and efficacy of new therapeutics in a diverse population of patients. This predictive power is integrated into our PhysioLab platforms, which have been used by our pharmaceutical and consumer product customers for over a decade to dramatically reduce the risk, time, and cost of product development.

11 Aug 2010

First complete sample-to-result, point-of-care DNA testing system for personalized medicine

Spartan Bioscience Inc., a privately held molecular diagnostics company that develops, manufactures, and markets DNA testing systems for on-demand applications, today announced the availability of the Spartan RX, the first complete sample-to-result, point-of-care DNA testing system for personalized medicine. The non-invasive and easy-to-use system provides automated results in one hour, enabling physicians to tailor treatments based on a patient's genotype faster than ever before.

11 Aug 2010

ACT signs agreement to select novel clinical candidates for two cancer metabolic programs

Advanced Cancer Therapeutics (ACT), a privately held company dedicated to bringing new anti-cancer therapies to market, today announced that it has signed an exclusive agreement to leverage the translational research expertise of Dr. Jason Chesney, Associate Professor, Department of Medicine at the University of Louisville's James Graham Brown Cancer Center (Brown Cancer Center), to identify new clinical candidates for the prevention and treatment of cancers against two key cancer metabolic targets.

11 Aug 2010

UT Southwestern enters partnership with Sun Yat-sen University to promote scientific research

UT Southwestern Medical Center has entered into an academic and scientific partnership with Sun Yat-sen University and its First Affiliated Hospital in Guangzhou, China. The first international institutional affiliation for UT Southwestern and a first step in implementing the global health initiative that is one of the medical center's current strategic priorities, the partnership was developed to promote joint scientific research, educational, and training activities.

10 Aug 2010

Isis second-quarter pro forma net operating loss increases to $15.5 million

Isis Pharmaceuticals, Inc. today announced its financial results for the quarter ended June 30, 2010. The Company finished the second quarter of 2010 with a pro forma net operating loss (NOL) of $15.5 million and $17.1 million for the three and six months ended June 30, 2010, respectively, compared to a pro forma net operating loss of $1.3 million and pro forma net operating income of $798,000 for the same periods of 2009.

9 Aug 2010

Health Canada approves first targeted biological therapy to show survival benefit in stomach cancer

Roche announced today that after priority review, Health Canada has approved HERCEPTIN(R) (trastuzumab), in combination with XELODA(R) (capecitabine) or intravenous 5-fluorouracil and cisplatin, for the first-line treatment of patients with HER2-positive metastatic adenocarcinoma of the stomach (gastric cancer) or gastro-esophageal cancer.

9 Aug 2010

Metabolism News and Research

Latest Metabolism News and Research

Study on differential aspects of cardiac insufficiency due to high blood pressure amongst women and men

Xcelligence System provides real-time detection of neuronal cell death

Genome-wide study identifies key genetic variant associated with nonalcoholic fatty liver disease

Research confirms genetic link to advanced fatty liver disease

Pisgah Labs receives Notice of Allowance for new patent relating to thyroid hormone drugs

Xenon Pharmaceuticals commences phase 2 clinical trial of XEN402 therapy for PHN

Zebrafish-yeast approach for studying copper deficiency, complex multifactorial diseases

Ancient discovery holds key to joint tissue regeneration

Albert Einstein College of Medicine named 1 of 5 Nathan Shock Centers

SIK2 impacts cell division cycle, regulates ovarian cancer response to chemotherapy: Research

Study finds first clue that links childhood obesity to skeletal fractures

Study examines impact of microvascular decompression surgery for type 2 diabetes

Scientists develop new metabolite analysis technique for accurate ovarian cancer detection

USPTO allows Regulus Therapeutics' claims of key Tuschl III patent covering Mir-155

Entelos receives patent for PhysioLab virtual patient technology

First complete sample-to-result, point-of-care DNA testing system for personalized medicine

ACT signs agreement to select novel clinical candidates for two cancer metabolic programs

UT Southwestern enters partnership with Sun Yat-sen University to promote scientific research

Isis second-quarter pro forma net operating loss increases to $15.5 million

Health Canada approves first targeted biological therapy to show survival benefit in stomach cancer

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut